Table 2. Signs and Solicited Symptoms during the 8-d Follow-Up Periods after Each Immunization.
FMP2.1/AS02A half dose | FMP2.1/AS02A full dose | Rabies Vaccine | ||||||||||||||||
Immunization 1 (n = 20) | Immunization 2 (n = 20) | Immunization 3 (n = 20) | Immunization 1 (n = 20) | Immunization 2 (n = 20) | Immunization 3 (n = 19) | Immunization 1 (n = 20) | Immunization 2 (n = 20) | Immunization 3 (n = 20) | ||||||||||
Overall | Grade 3 | Overall | Grade 3 | Overall | Grade 3 | Overall | Grade 3 | Overall | Grade 3 | Overall | Grade 3 | Overall | Grade 3 | Overall | Grade 3 | Overall | Grade 3 | |
Local | ||||||||||||||||||
Pain (%) | 19 (95) | 0 | 15 (75) | 0 | 11 (55) | 0 | 20 (100) | 0 | 19 (95) | 0 | 14 (73.7) | 0 | 6 (30) | 0 | 10 (50) | 0 | 6 (30) | 0 |
Swelling (%) | 13 (65) | 1 (5) | 11 (55) | 3 (15) | 7 (35) | 2 (10) | 13 (65) | 7 (35) | 10 (50) | 7 (35) | 8 (42.1) | 7 (35) | 3 (15) | 1 (5) | 3 (15) | 3 (15) | 4 (20) | 1 (5) |
Limitation of arm motion (%) | 4 (20) | 0 | 1 (5) | 0 | 0 | 0 | 1 (5) | 0 | 2 (10) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Erythema (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
General | ||||||||||||||||||
Fever (%) | 3 (15) | 0 | 1 (5) | 0 | 2 (10) | 0 | 2 (10) | 0 | 1 (5) | 0 | 3 (15.7) | 0 | 0 | 0 | 1 (5) | 0 | 0 | 0 |
Headache (%) | 5 (25) | 0 | 1 (5) | 0 | 1 (5) | 0 | 5 (25) | 0 | 8 (40) | 0 | 4 (21) | 0 | 2 (10) | 0 | 4 (20) | 0 | 3 (15) | 0 |
Joint pain (%) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (5) | 0 | 1 (5) | 0 | 0 | 0 | 0 | 0 | 1 (5) | 0 | 0 | 0 |
Myalgia (%) | 2 (10) | 0 | 0 | 0 | 1 (5) | 0 | 3 (15) | 0 | 1 (5) | 0 | 2 (10.5) | 0 | 0 | 0 | 3 (15) | 0 | 0 | 0 |
Malaise (%) | 3 (15) | 0 | 0 | 0 | 1 (5) | 0 | 2 (10) | 0 | 2 (10) | 0 | 1 (5.3) | 0 | 0 | 0 | 3 (15) | 0 | 0 | 0 |
Nausea (%) | 2 (10) | 0 | 1 (5) | 0 | 1 (5) | 0 | 0 | 0 | 1 (5) | 0 | 0 | 0 | 0 | 0 | 1 (5) | 0 | 0 | 0 |
Chills (%) | 3 (15) | 0 | 1 (5) | 0 | 0 | 0 | 1 (5) | 0 | 1 (5) | 0 | 0 | 0 | 0 | 0 | 1 (5) | 0 | 0 | 0 |